Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis NCT01519349 | Follistatin 344 | Phase 1 | Completed | Nationwide Children's Hospital | 15 | Oct 2017 | Oct 2, 2023 |
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight NCT04881760 | Retatrutide | Phase 2 | Completed | Eli Lilly and Company | 338 | May 16, 2022 | Sep 13, 2023 |
A Study of LY3457263 in Obese Participants NCT05582096 | Nisotirostide | Phase 1 | Completed | Eli Lilly and Company | 38 | Jun 8, 2023 | Jul 18, 2023 |
A Study of LY3437943 in Participants With Type 2 Diabetes NCT04867785 | Retatrutide | Phase 2 | Completed | Eli Lilly and Company | 281 | Jul 8, 2022 | Jul 3, 2023 |
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. NCT04153929 | Survodutide | Phase 2 | Completed | Boehringer Ingelheim | 413 | Oct 8, 2021 | Nov 29, 2022 |
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms NCT03569007 | Larazotide | Phase 3 | Terminated | 9 Meters Biopharma, Inc. | 307 | Jul 21, 2022 | Jul 26, 2022 |
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling NCT01438073 | Kisspeptin-10 | Phase 1 | Completed | Massachusetts General Hospital | 96 | Apr 2016 | Jul 11, 2022 |
Intratumoral Injections of LL37 for Melanoma NCT02225366 | LL-37 | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | Nov 24, 2020 | Dec 9, 2021 |
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese NCT03600480 | Cagri-Sema, Cagrilintide | Phase 1 | Completed | Novo Nordisk A/S | 96 | Jun 12, 2020 | Nov 17, 2021 |
Oral LAT8881 in Neuropathic Pain NCT03865953 | AOD-9604 | Phase 2 | Completed | Lateral Pharma Pty Ltd | 53 | Apr 19, 2020 | Jun 14, 2021 |
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine NCT04153409 | AOD-9604 | Phase 2 | Completed | Lateral Pharma Pty Ltd | 21 | Feb 15, 2020 | Apr 28, 2021 |
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers NCT04555824 | TB-500 | Phase 1 | Completed | Beijing Northland Biotech. Co., Ltd. | 54 | Feb 20, 2018 | Sep 29, 2020 |
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers NCT04555850 | TB-500 | Phase 1 | Completed | Beijing Northland Biotech. Co., Ltd. | 30 | Feb 18, 2019 | Sep 29, 2020 |
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 NCT03838185 | J-147 | Phase 1 | Completed | Abrexa Pharmaceuticals, Inc. | 64 | Feb 1, 2020 | Sep 3, 2020 |
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity NCT01262664 | Adipotide | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | Jan 2, 2019 | Jan 4, 2019 |
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease NCT00889473 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 42 | Nov 2009 | Sep 20, 2017 |
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease NCT01396213 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 342 | Aug 20, 2013 | Sep 20, 2017 |
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients NCT01925209 | Bimagrumab | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 251 | Jan 6, 2016 | Aug 11, 2017 |
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis NCT02039687 | ARA-290 | Phase 2 | Completed | Araim Pharmaceuticals, Inc. | 64 | Jan 2015 | Apr 18, 2017 |
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus NCT00672074 | Ipamorelin | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 117 | Dec 2009 | Apr 14, 2017 |
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function NCT01280344 | Ipamorelin | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 320 | Jun 2013 | Apr 13, 2017 |
A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism NCT02369796 | Kisspeptin-10 | Phase 2 | Terminated | Takeda | 15 | Oct 2015 | Mar 31, 2017 |
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes NCT01167881 | ATX-304 | Phase 3 | Completed | Boehringer Ingelheim | 1,549 | Aug 2013 | Sep 2, 2016 |
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia NCT01963598 | Trevogrumab | Phase 2 | Completed | Regeneron Pharmaceuticals | 253 | Jan 2015 | Mar 28, 2016 |
TH9507 in Patients With HIV-Associated Lipodystrophy NCT00123253 | Tesamorelin | Phase 3 | Completed | Theratechnologies | 412 | Nov 2006 | Nov 27, 2013 |
TH9507 in Patients With HIV-Associated Lipodystrophy NCT00435136 | Tesamorelin | Phase 3 | Completed | Theratechnologies | 412 | Nov 2006 | Nov 27, 2013 |
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) NCT00148486 | Tesofensine | Phase 2 | Completed | Boehringer Ingelheim | 261 | Mar 2005 | Oct 29, 2013 |
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations NCT00148512 | Tesofensine | Phase 2 | Completed | Boehringer Ingelheim | 254 | Feb 2005 | Oct 29, 2013 |
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer’s Type NCT00153010 | Tesofensine | Phase 2 | Completed | Boehringer Ingelheim | 430 | Mar 2005 | Oct 29, 2013 |
Effect of Tesofensine on Weight Reduction in Patients With Obesity. NCT00394667 | Tesofensine | Phase 2 | Completed | NeuroSearch A/S | 200 | Not stated | Apr 22, 2013 |
Evaluation of Long Term Safety of Tesofensine in Patients With Obesity NCT00481104 | Tesofensine | Phase 2 | Completed | NeuroSearch A/S | 140 | Sep 2008 | Jul 4, 2011 |
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes NCT00508287 | ATX-304 | Phase 1 | Completed | Bristol-Myers Squibb | 36 | Nov 2007 | Mar 16, 2009 |
Effect of Tesofensine on Energy Balance in Humans. NCT00428415 | Tesofensine | Phase 1 / Phase 2 | Completed | NeuroSearch A/S | 32 | Dec 2007 | Mar 5, 2008 |
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity NCT00267527 | CJC-1295 with DAC | Phase 2 | Terminated | ConjuChem | 120 | Not stated | Oct 16, 2006 |